SHENZHEN Hemogen Therapeutic Co., Ltd.

Chiang Mai, Thailand — November 24, 2025Hemogen Therapeutics was invited to participate in the inaugural meeting of the Southeast Asia Thalassemia Pre...

On November 14, 2025, the Joint Regulatory Mechanism Office for the Cross-Border Management of Special Biomedical Items in Shenzhen announced the prop...

Shenzhen, China — November 2025Hemogen Therapeutic announced that it has been awarded the “Outstanding Clinical Achievement in Cell Therapy” at the 14...

In the field of cell and gene therapy (CGT), efficient and stable cell purification and elutriation are the core links to ensure efficacy and safety. ...

Shenzhen Hemogen Therapeutic Co., Ltd. (hereinafter referred to as “Hemogen”) has achieved a significant milestone in its international...

Thalassemia is a rare, inherited blood disorder caused by mutations in the genes involved in hemoglobin production that cause the body to produce less...

Recently, the Science and Technology Innovation Bureau of Yantian District, Shenzhen, issued the "Interim Measures for the Recognition and Manage...

On December 19, 2023, Hemogen Biotechnology Co., Ltd. (Hemogen), based in Shenzhen, successfully obtained the IND（investigational new drug) approval f...